View Author
myeloma patient thalidomide study analysis hovon factor blood association treatment trial pathway bortezomib validation -50 effect erasmus mc table number neuropathy group thrombosis cancer discovery intron dexamethasone myeloma patients response result combination sample figure dataset research level coding-nonsynonymou j clin oncol apoptosi mrc myeloma ix br j haematol cytokine thalidomide-related p value control erasmu panel j thromb haemost thalidomide exposure identi hovon -65/gmmg trial .999 czech republic myeloma cells venou library 2011. therapy tissue factor mechanism december volume aspirin event pointwise exposure variation vte risk fication prothrombotic thalidomide vtes al blood johnson polymorphism onset disease distribution 2008. ifm 2005-01 trial genotyping approach
2 Most Recent Publications
|
Genetic factors underlying the risk of bortezomib induced peripheral neuropathy in multiple myeloma patients
(Article)
Corthals, S.L. Kuiper, R. Johnson, D.C. Sonneveld, P. Hajek, R. Holt, B. van der Magrangeas, F. Goldschmidt, H. Morgan, G. Avet-Loiseau, H. |
2011-11-01
|
|
Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping
(Article)
Johnson, D.C. Corthals, S.L. Jackson, G. Baris, D. Rajkumar, S.V. Davies, F. Durie, B.G.M. Crowley, J. Sonneveld, P. Ness, B. van Morgan, G. Ramos, C. Hoering, A. Cocks, K. Dickens, N.J. Haessler, J. Goldschmidt, H. Child, J.A. Bell, S.E. |
2008-12-15
|
